CN107073138B - 降低由pd-l1诱导的免疫耐受性 - Google Patents

降低由pd-l1诱导的免疫耐受性 Download PDF

Info

Publication number
CN107073138B
CN107073138B CN201680002926.1A CN201680002926A CN107073138B CN 107073138 B CN107073138 B CN 107073138B CN 201680002926 A CN201680002926 A CN 201680002926A CN 107073138 B CN107073138 B CN 107073138B
Authority
CN
China
Prior art keywords
cells
cell
modified
car
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680002926.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN107073138A (zh
Inventor
吴昭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Xuxu Technology Co ltd
Original Assignee
Sidansai Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sidansai Biotechnology Co Ltd filed Critical Sidansai Biotechnology Co Ltd
Priority to CN201810281004.XA priority Critical patent/CN108410892B/zh
Publication of CN107073138A publication Critical patent/CN107073138A/zh
Application granted granted Critical
Publication of CN107073138B publication Critical patent/CN107073138B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
CN201680002926.1A 2015-03-02 2016-03-01 降低由pd-l1诱导的免疫耐受性 Active CN107073138B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810281004.XA CN108410892B (zh) 2015-03-02 2016-03-01 降低由pd-l1诱导的免疫耐受性

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562126804P 2015-03-02 2015-03-02
US62/126,804 2015-03-02
PCT/CN2016/075061 WO2016138846A1 (en) 2015-03-02 2016-03-01 Reducing immune tolerance induced by pd‐l1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810281004.XA Division CN108410892B (zh) 2015-03-02 2016-03-01 降低由pd-l1诱导的免疫耐受性

Publications (2)

Publication Number Publication Date
CN107073138A CN107073138A (zh) 2017-08-18
CN107073138B true CN107073138B (zh) 2018-06-29

Family

ID=56848306

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680002926.1A Active CN107073138B (zh) 2015-03-02 2016-03-01 降低由pd-l1诱导的免疫耐受性
CN201810281004.XA Active CN108410892B (zh) 2015-03-02 2016-03-01 降低由pd-l1诱导的免疫耐受性

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810281004.XA Active CN108410892B (zh) 2015-03-02 2016-03-01 降低由pd-l1诱导的免疫耐受性

Country Status (11)

Country Link
US (4) US9572837B2 (enExample)
EP (2) EP3089761B1 (enExample)
JP (2) JP6336684B2 (enExample)
KR (1) KR102133857B1 (enExample)
CN (2) CN107073138B (enExample)
AU (1) AU2016228080B2 (enExample)
BR (1) BR112017018770A2 (enExample)
CA (1) CA2976684C (enExample)
RU (1) RU2688692C2 (enExample)
SG (1) SG11201706947TA (enExample)
WO (1) WO2016138846A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
PL3253865T3 (pl) 2015-02-06 2022-10-10 National University Of Singapore Sposoby wzmacniania skuteczności terapeutycznych komórek odpornościowych
EP3089761B1 (en) * 2015-03-02 2019-06-12 Innovative Cellular Therapeutics Co., Ltd. Reducing immune tolerance induced by pd l1
DK3298033T4 (da) 2015-05-18 2023-10-02 Tcr2 Therapeutics Inc Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner
HK1258041A1 (zh) 2015-09-04 2019-11-01 纪念斯隆-凯特林癌症中心 免疫细胞组合物和使用方法
CN109072194B (zh) 2015-12-09 2022-12-27 纪念斯隆-凯特林癌症中心 免疫细胞组合物及其使用方法
EP4286522A3 (en) * 2016-03-23 2024-02-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
EP3988111A1 (en) 2016-04-01 2022-04-27 Innovative Cellular Therapeutics Holdings, Ltd. Use of chimeric antigen receptor modified cells to treat cancer
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
EP3507361A1 (en) 2016-08-30 2019-07-10 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use for treating viral and other infections
WO2018064921A1 (en) * 2016-10-06 2018-04-12 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP7778468B2 (ja) 2016-11-22 2025-12-02 ナショナル ユニバーシティ オブ シンガポール Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断
CN108148862B (zh) * 2016-12-05 2019-03-08 上海优卡迪生物医药科技有限公司 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用
US20190358263A1 (en) 2016-12-07 2019-11-28 Oslo Universitetssykehus Hf Compositions and Methods for Cell Therapy
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy
EP3592368A1 (en) * 2017-03-08 2020-01-15 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
CN110753555A (zh) 2017-04-19 2020-02-04 得克萨斯州大学系统董事会 表达工程化抗原受体的免疫细胞
SG11202000402PA (en) 2017-08-10 2020-02-27 Nat Univ Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
WO2019067504A1 (en) * 2017-09-26 2019-04-04 Longwood University SPECIFIC CHIMERIC ANTIGEN RECEPTOR AT PD-1 AS IMMUNOTHERAPY
CN109836493A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向cd19的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
US10561686B2 (en) * 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
CN120154716A (zh) 2018-01-22 2025-06-17 恩多塞特公司 Car t细胞的使用方法
JP7774961B2 (ja) 2018-02-06 2025-11-25 シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート フルオレセイン結合エーテルリン脂質（ｆｌ－ｐｌｅ）で標識された腫瘍に対して最適なｔ細胞機能を示すフルオレセイン特異的ｃａｒ
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
AU2019275076B2 (en) 2018-05-23 2024-12-19 National University Of Singapore Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
EP3870146A4 (en) * 2018-10-25 2022-08-10 Innovative Cellular Therapeutics Holdings, Ltd. Increase or maintaining t-cell subpopulations in adoptive t-cell therapy
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
WO2020116686A1 (ko) 2018-12-06 2020-06-11 고려대학교 산학협력단 인간 항-antxr 키메라 항원 수용체 및 이의 용도
CN109971842A (zh) * 2019-02-15 2019-07-05 成都美杰赛尔生物科技有限公司 一种检测CRISPR-Cas9脱靶效应的方法
WO2020172555A1 (en) * 2019-02-21 2020-08-27 Regents Of The University Of Minnesota Genetically modified gamma delta t cells and methods of making and using
AU2020232216B2 (en) * 2019-03-01 2025-09-25 Allogene Therapeutics, Inc. Chimeric cytokine receptors bearing a PD-1 ectodomain
JP2022531814A (ja) * 2019-03-12 2022-07-12 イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ 改変細胞の増幅およびその応用
US11739136B2 (en) * 2019-03-18 2023-08-29 Innovative Cellular Therapeutics Holdings, Ltd. Inducible dominant negative PD-1 and uses in adoptive cell therapy
CN109868263A (zh) * 2019-03-29 2019-06-11 深圳精准医疗科技有限公司 重组单纯疱疹病毒及其制备方法和应用、重组载体的构建方法及其应用
AU2020276117A1 (en) * 2019-05-16 2021-12-09 Memorial Sloan-Kettering Cancer Center Mesothelin cars and uses thereof
CN110423767A (zh) * 2019-07-12 2019-11-08 华东师范大学 表达可溶性pd-1的嵌合抗原受体car基因及应用
CN110592140A (zh) * 2019-09-30 2019-12-20 王清路 Pd-1基因缺陷型pd-1-cart细胞制剂的制法
US20210137983A1 (en) * 2019-11-08 2021-05-13 Innovative Cellular Therapeutics Holdings, Ltd. Nk cell expansion and uses thereof
KR102674654B1 (ko) 2019-11-26 2024-06-12 난트퀘스트, 인크. 일차 nk car 구축물 및 방법
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
JP7198302B2 (ja) * 2021-03-08 2022-12-28 一般財団法人 化学物質評価研究機構 Ｐｄ－１を介した免疫チェックポイント阻害剤の生物活性試験法
US20230227779A1 (en) 2022-01-19 2023-07-20 Innovative Cellular Therapeutics Holdings, Ltd. Enhanced Chimeric Antigen Receptor Cells in Hypoxic Tumor Microenvironment
WO2025184170A1 (en) * 2024-02-27 2025-09-04 Overt Bio, Inc. Methods and compositions for improving t cell function in an immunosuppressive environment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019615A2 (en) * 2011-07-29 2013-02-07 The Trustees Of The University Of Pennsylvania Switch costimulatory receptors
CN103492406A (zh) * 2010-12-09 2014-01-01 宾夕法尼亚大学董事会 嵌合抗原受体-修饰的t细胞治疗癌症的用途
WO2014059173A2 (en) * 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
WO2014145252A2 (en) * 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CN104718284A (zh) * 2012-05-25 2015-06-17 塞勒克提斯公司 工程化用于免疫疗法的异体和免疫抑制耐受性t细胞的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
WO2003022875A2 (en) * 2001-09-07 2003-03-20 Everygene Ab Polymorphisms of pd-1
KR101471647B1 (ko) * 2011-10-26 2014-12-11 국립암센터 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
KR102363191B1 (ko) * 2013-02-26 2022-02-17 메모리얼 슬로안 케터링 캔서 센터 면역치료용 조성물 및 방법
CN105431449B (zh) 2013-04-05 2021-08-24 港大科桥有限公司 新的pd1同种型及其用于加强免疫应答的用途
KR102164455B1 (ko) 2013-05-08 2020-10-13 삼성전자주식회사 콘텐트 제공 방법, 콘텐트 제공 장치 및 그 콘텐트 제공 시스템
JP6603209B2 (ja) * 2013-05-10 2019-11-06 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾
EP3811970A1 (en) 2014-03-15 2021-04-28 Novartis AG Regulatable chimeric antigen receptor
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
ES2819451T3 (es) * 2014-08-08 2021-04-16 Univ Leland Stanford Junior Agentes PD-1 de alta afinidad y procedimientos de uso
EP3089761B1 (en) 2015-03-02 2019-06-12 Innovative Cellular Therapeutics Co., Ltd. Reducing immune tolerance induced by pd l1
US10493139B2 (en) 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
HK1258041A1 (zh) 2015-09-04 2019-11-01 纪念斯隆-凯特林癌症中心 免疫细胞组合物和使用方法
EP3362074B1 (en) 2015-10-16 2023-08-09 President and Fellows of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
CN109072194B (zh) 2015-12-09 2022-12-27 纪念斯隆-凯特林癌症中心 免疫细胞组合物及其使用方法
CN112088008B (zh) 2018-01-11 2024-01-02 浙江煦顼技术有限公司 修饰细胞的扩增及其用途
EP3870146A4 (en) 2018-10-25 2022-08-10 Innovative Cellular Therapeutics Holdings, Ltd. Increase or maintaining t-cell subpopulations in adoptive t-cell therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103492406A (zh) * 2010-12-09 2014-01-01 宾夕法尼亚大学董事会 嵌合抗原受体-修饰的t细胞治疗癌症的用途
WO2013019615A2 (en) * 2011-07-29 2013-02-07 The Trustees Of The University Of Pennsylvania Switch costimulatory receptors
CN104718284A (zh) * 2012-05-25 2015-06-17 塞勒克提斯公司 工程化用于免疫疗法的异体和免疫抑制耐受性t细胞的方法
WO2014059173A2 (en) * 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
WO2014145252A2 (en) * 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo;Michael C. Milone，等;《Molecular Therapy》;20090421;第17卷(第8期);参见第1453-1464页 *
PD-1– and CTLA-4–based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses;Victor D. Fedorov，等;《Sci Transl Med.》;20131211;第5卷(第215期);第1-25页 *
sPD-1封闭PD-L促进抗瘤免疫的机制研究;贺兰湘，等;《中华微生物学和免疫学杂志》;20060531;第26卷(第5期);第463-467页 *

Also Published As

Publication number Publication date
SG11201706947TA (en) 2017-09-28
RU2017130985A3 (enExample) 2019-03-04
CN108410892B (zh) 2021-05-28
CA2976684C (en) 2024-03-05
US10619136B2 (en) 2020-04-14
US20210079349A1 (en) 2021-03-18
BR112017018770A2 (pt) 2018-04-17
US20160256488A1 (en) 2016-09-08
US9572837B2 (en) 2017-02-21
US11932873B2 (en) 2024-03-19
JP2018064568A (ja) 2018-04-26
CN107073138A (zh) 2017-08-18
EP3549612B1 (en) 2025-04-30
JP2018508539A (ja) 2018-03-29
RU2017130985A (ru) 2019-03-04
KR102133857B1 (ko) 2020-07-20
AU2016228080B2 (en) 2020-11-12
US20170096638A1 (en) 2017-04-06
EP3089761A1 (en) 2016-11-09
US10865382B2 (en) 2020-12-15
RU2688692C2 (ru) 2019-05-22
EP3089761A4 (en) 2017-05-10
CA2976684A1 (en) 2016-09-09
WO2016138846A1 (en) 2016-09-09
US20190316086A1 (en) 2019-10-17
AU2016228080A1 (en) 2017-09-07
EP3549612A1 (en) 2019-10-09
JP6336684B2 (ja) 2018-06-06
KR20170124576A (ko) 2017-11-10
CN108410892A (zh) 2018-08-17
EP3089761B1 (en) 2019-06-12
JP6767347B2 (ja) 2020-10-14

Similar Documents

Publication Publication Date Title
US11932873B2 (en) Reducing immune tolerance induced by PD-L1
US20240218075A1 (en) Use of chimeric antigen receptor modified cells to treat cancer
US20180223255A1 (en) Activation and Expansion of T Cells
US11773384B2 (en) Chimeric antigen receptor (CAR) and T cell receptor (TCR) modified T cells
CN110257338B (zh) 嵌合细胞因子受体
WO2018064921A1 (en) Use of chimeric antigen receptor modified cells to treat cancer
CN110540997B (zh) 靶向bcma嵌合抗原受体、核酸序列、载体及应用
HK1228783A1 (en) Reducing immune tolerance induced by pd l1
HK1228783B (en) Reducing immune tolerance induced by pd l1
HK40073625A (en) Use of chimeric antigen receptor modified cells to treat cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20211130

Address after: 201203 floor 3, building 1, No. 6055, Jinhai Road, Fengxian District, Shanghai

Patentee after: Shanghai Xuxu Technology Co.,Ltd.

Address before: 201203 Room 201, building 4, 998 HaLei Road, Pudong New Area, Shanghai

Patentee before: SHANGHAI SIDANSAI BIOTECHNOLOGY CO.,LTD.

TR01 Transfer of patent right
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: No. 29, 1st Floor, Building 2, No. 198 Peninsula Middle Road, Dipu Street, Anji County, Huzhou City, Zhejiang Province, 313300 (self declared)

Patentee after: Zhejiang Xuxu Technology Co.,Ltd.

Address before: 201203 floor 3, building 1, No. 6055, Jinhai Road, Fengxian District, Shanghai

Patentee before: Shanghai Xuxu Technology Co.,Ltd.

PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Reduce immune tolerance induced by PD-L1

Effective date of registration: 20231124

Granted publication date: 20180629

Pledgee: Industrial Bank Co.,Ltd. Shanghai Branch

Pledgor: Zhejiang Xuxu Technology Co.,Ltd.

Registration number: Y2023310000772

PE01 Entry into force of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Granted publication date: 20180629

Pledgee: Industrial Bank Co.,Ltd. Shanghai Branch

Pledgor: Zhejiang Xuxu Technology Co.,Ltd.

Registration number: Y2023310000772

PC01 Cancellation of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Reduce immune tolerance induced by PD-L1

Granted publication date: 20180629

Pledgee: Industrial Bank Co.,Ltd. Shanghai Hongqiao Branch

Pledgor: Zhejiang Xuxu Technology Co.,Ltd.

Registration number: Y2024310001284

PE01 Entry into force of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Granted publication date: 20180629

Pledgee: Industrial Bank Co.,Ltd. Shanghai Hongqiao Branch

Pledgor: Zhejiang Xuxu Technology Co.,Ltd.

Registration number: Y2024310001284

PC01 Cancellation of the registration of the contract for pledge of patent right